Walleye Trading
DNLI icon

Walleye Trading’s Denali Therapeutics DNLI Stock Holding History

Walleye Trading’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-305,800
Closed -$7.05M – 4795
2023
Q1 		$7.05M Buy
+305,800
New +$8.42M 0.02% 805
2021
Q2 		– Sell
-1,300
Closed -$74K – 5229
2021
Q1 		$74K Buy
+1,300
New +$87K ﹤0.01% 4208

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Walleye Trading's DNLI Position: Q2 2023 in Review

Walleye Trading sold out of Denali Therapeutics (DNLI) in Q2 2023, closing a stake of 226,753 shares — an estimated $5.22M sold.

Walleye Trading first reported a position in DNLI in Q4 2020 and held it in 3 quarters. The position peaked at $5.22M in Q1 2023. 203 funds tracked by Wall St. Rank hold DNLI as of Q2 2023.

  • Walleye Trading reported no remaining Denali Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Walleye Trading sold 226,753 Denali Therapeutics shares in Q2 2023, an estimated $5.22M.
  • Walleye Trading first reported a position in Denali Therapeutics in Q4 2020 and held it in 3 quarters.
  • Walleye Trading's Denali Therapeutics position peaked at $5.22M in Q1 2023.
  • 203 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2023.

Based on Walleye Trading's 13F filing for Q2 2023, filed 14 Aug 2023.